Close Menu

NEW YORK, May 24 – Lynx Therapeutics said Thursday it had received a cash injection of $11.1 million in a private placement from a group of seven unnamed investors led by HBK Master Fund.

The new funds will help to shore up the companies dwindling resources as it continues developing its products and building its business. As of March 31, 2001, Lynx had $11.9 million in cash and cash equivalents.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.